Form D · Pharmaceuticals
Actinium Pharmaceuticals, Inc.
New York, NY · CIK 0001328440
Offering snapshot reported Dec 31, 2012 · SEC filing
- Reported sold
- $5.14M Offering amount: $15M
- Investors reported
- 108 Form D · investor count
- Minimum accepted
- $3K Reported outside-investor minimum
- First sale
- Dec 19, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 31, 2012 | Initial | $5,141,450 | No comparison | 108 | SEC filing |
| Nov 3, 2011 | Initial | $364,000 | No comparison | 11 | SEC filing |
| Oct 17, 2011 | Initial | $4,125,025 | No comparison | 65 | SEC filing |
| Apr 17, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 9, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 20, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 24, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $618K
- Finders' fees
- $0
- Form D file number
- 021-189157
This offering also has a $5,000,000 overallotment that can be sold if there is sufficient demand.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Laidlaw & Company (UK) Ltd. | 119037 |
Source: Form D, filed Dec 31, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dragan Cicic | Executive |
| Enza Guagenti | Executive |
| Rosemary Mazanet | Director |
| David Nicholson | Director |
| Sandesh Seth | Director |
| Richard Sherman | Director, Executive |
| Jack V. Talley | Director, Executive |
| Sergio Traversa | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
501 Fifth Avenue, 3rd Floor
New York, NY, 10017
New York, NY, 10017